Opportunities in the Global Refractory Follicular Lymphoma Diagnostics Market include the growing need for MRD monitoring and liquid biopsies, driven by the rise in hematologic malignancies. The surge ...
Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of Paige Predict, a suite of cutting-edge digital pathology ...
Regulatory deregulation and liquid biopsy adoption pushing the rapid growth of the oncology companion diagnostic market. In ...
SPOKANE INDIAN RESERVATION, Wash. – Officials from the Spokane Tribe Department of Natural Resources have announced the first suspected positive case of Chronic Wasting Disease (CWD) on the Spokane ...
The Missouri Department of Conservation has added 12 new counties to its list of those requiring hunters to bring in their deer to test for chronic wasting disease, or CWD, on the opening weekend of ...
NSCLC Oncogenic Driver Mutations: Where Do We Stand?
Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation ...
NEW YORK – Patients seeking treatment for advanced lung cancer are now evaluated for HER2 alterations via several tests in a fragmented process that can lead to extra biopsies and less-than-optimal ...
The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency. The mismatch repair immunohistochemical panel pharmDx (Dako Omnis) has received U.S.
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback